Fibrocell Announces Initiation of Patient Recruitment in Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
June 13, 2016 08:00 ET
|
Fibrocell Science, Inc.
EXTON, Pa., June 13, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for...
Fibrocell Reports Phase II azficel-T Trial for Treatment of Vocal Cord Scarring Did Not Meet Primary Endpoints
June 08, 2016 08:00 ET
|
Fibrocell Science, Inc.
EXTON, Pa., June 08, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing transformational therapies for diseases...
Fibrocell Reports First Quarter 2016 Financial Results and Operational Highlights
May 05, 2016 08:00 ET
|
Fibrocell Science Inc.
EXTON, Pa., May 05, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing transformational therapies for diseases...
Fibrocell to Host Conference Call and Webcast on Thursday, May 5, 2016 to Discuss First Quarter 2016 Financial Results and Recent Operational Highlights
April 28, 2016 08:00 ET
|
Fibrocell Science Inc.
EXTON, Pa., April 28, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing transformational therapies for diseases...
Fibrocell Receives Orphan Drug Designation from the FDA for FCX-013 for the Treatment of Localized Scleroderma
April 25, 2016 08:00 ET
|
Fibrocell Science Inc.
EXTON, Pa., April 25, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing transformational therapies for diseases...
Fibrocell Announces Last Patient Visit for Primary Endpoint Analysis in Phase II Clinical Trial of azficel-T for the Treatment of Vocal Cord Scarring
April 21, 2016 08:00 ET
|
Fibrocell Science Inc.
Primary Endpoint Results Expected in Second Quarter of 2016 Personalized Biologics Pipeline Advancing in Skin and Connective Tissue EXTON, Pa., April 21, 2016 (GLOBE NEWSWIRE) -- Fibrocell...
Fibrocell and Intrexon Announce Allowance to Commence Phase I/II Trial for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
- Phase I/II Clinical Trial to Begin in Second Quarter of 2016 - EXTON, Pa. and GERMANTOWN, Md., April 18, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell...
Fibrocell to Present at the Alliance for Regenerative Medicine’s 4th Annual Cell & Gene Therapy Investor Day
March 15, 2016 08:00 ET
|
Fibrocell Science Inc.
EXTON, Pa., March 15, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing transformational therapies for diseases...
Fibrocell Reports Fourth Quarter and Full Year 2015 Financial Results and Operational Highlights
March 10, 2016 08:00 ET
|
Fibrocell Science Inc.
EXTON, Pa., March 10, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing transformational therapies for diseases...
Fibrocell to Present at 28th Annual ROTH Conference
March 08, 2016 08:00 ET
|
Fibrocell Science Inc.
EXTON, Pa., March 08, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing transformational therapies for diseases...